Charlotte Teunissen

Discovering markers of disease progression in patients with MS treated with natalizumab 2:08
Discovering markers of disease progression in patients with MS treated with natalizumab
Charlotte Teunissen • 6 Oct 2021
Markers of axonal damage in progressive MS 1:19
Markers of axonal damage in progressive MS
Charlotte Teunissen • 6 Oct 2021
Emerging biomarkers in MS: CNTN1 and GFAP 4:13
Emerging biomarkers in MS: CNTN1 and GFAP
Charlotte Teunissen • 6 Oct 2021
The future of biomarkers in MS: novel discoveries and defining protocols 2:12
The future of biomarkers in MS: novel discoveries and defining protocols
Charlotte Teunissen • 6 Oct 2021
NfL to monitor treatment effects in MS 3:26
NfL to monitor treatment effects in MS
Charlotte Teunissen • 4 Jun 2021
Novel biomarkers to predict progression in MS 4:28
Novel biomarkers to predict progression in MS
Charlotte Teunissen • 4 Jun 2021
Diagnosing Alzheimer’s disease using blood-based biomarkers 2:31
Diagnosing Alzheimer’s disease using blood-based biomarkers
Charlotte Teunissen • 4 Jun 2021
Low serum contactin-1 predicts disability progression in MS 4:27
Low serum contactin-1 predicts disability progression in MS
Charlotte Teunissen • 4 Jun 2021
The content of VJNeurology is intended for healthcare professionals